Intervention Review

You have free access to this content

Drugs for preventing malaria in travellers

  1. Frederique A Jacquerioz1,*,
  2. Ashley M Croft2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 6 AUG 2009

DOI: 10.1002/14651858.CD006491.pub2

Database Title

Additional Information

How to Cite

Jacquerioz FA, Croft AM. Drugs for preventing malaria in travellers. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD006491. DOI: 10.1002/14651858.CD006491.pub2.

Author Information

  1. 1

    Tulane School of Public Health and Tropical Medicine, Center for Evidence-Based Global Health, New Orleans, Louisiana, USA

  2. 2

    Surgeon General's Department, London, UK

*Frederique A Jacquerioz, Center for Evidence-Based Global Health, Tulane School of Public Health and Tropical Medicine, 1440 Canal Street, TDW, Ste 1820, New Orleans, Louisiana, 70115, USA. fjacque@tulane.edu.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JAN 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (61K)Standard (631K)Full (843K)
[Figure 1]
Figure 1.
[Figure 2]
Figure 2.
[Figure 3]
Figure 3. Forest plot of comparison: 2 Atovaquone-proguanil vs mefloquine, outcome: 2.1 Any adverse outcome.
[Figure 4]
Figure 4. Forest plot of comparison: 2 Atovaquone-proguanil vs mefloquine, outcome: 2.3 Any gastrointestinal adverse outcome.
[Figure 5]
Figure 5. Forest plot of comparison: 2 Atovaquone-proguanil vs mefloquine, outcome: 2.4 Any neuropsychiatric adverse outcome.
[Figure 6]
Figure 6. Forest plot of comparison: 2 Atovaquone-proguanil vs mefloquine, outcome: 2.7 Total Mood Disturbance (TMD) scores.
[Figure 7]
Figure 7. Forest plot of comparison: 3 Doxycycline vs mefloquine, outcome: 3.5 Any neuropsychiatric adverse outcome.
[Figure 8]
Figure 8. Forest plot of comparison: 4 Any standard drugs vs chloroquine-proguanil, outcome: 4.2 Any adverse outcome.
[Figure 9]
Figure 9. Forest plot of comparison: 4 Any standard drugs vs chloroquine-proguanil, outcome: 4.4 Any gastrointestinal adverse outcome.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Atovaquone-proguanil vs doxycycline, Outcome 1 Any adverse outcome.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Atovaquone-proguanil vs doxycycline, Outcome 2 Dermatological adverse outcome.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Atovaquone-proguanil vs doxycycline, Outcome 3 Gastrointestinal adverse outcome.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Atovaquone-proguanil vs doxycycline, Outcome 4 Neuropsychiatric adverse outcome.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Atovaquone-proguanil vs doxycycline, Outcome 5 Discontinuation of study drug for any reason.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Atovaquone-proguanil vs mefloquine, Outcome 1 Any adverse outcome.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Atovaquone-proguanil vs mefloquine, Outcome 2 Dermatological adverse outcome.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Atovaquone-proguanil vs mefloquine, Outcome 3 Gastrointestinal adverse outcome.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Atovaquone-proguanil vs mefloquine, Outcome 4 Neuropsychiatric adverse outcome.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Atovaquone-proguanil vs mefloquine, Outcome 5 Serious adverse event.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Atovaquone-proguanil vs mefloquine, Outcome 6 Discontinuation of study drug for any reason.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Atovaquone-proguanil vs mefloquine, Outcome 7 Total Mood Disturbance (TMD) scores.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Doxycycline vs mefloquine, Outcome 1 Clinical cases of malaria.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Doxycycline vs mefloquine, Outcome 2 Any adverse outcome.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Doxycycline vs mefloquine, Outcome 3 Dermatological adverse outcome.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Doxycycline vs mefloquine, Outcome 4 Gastrointestinal adverse outcome.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Doxycycline vs mefloquine, Outcome 5 Neuropsychiatric adverse outcome.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Doxycycline vs mefloquine, Outcome 6 Discontinuation of study drug for any reason.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Any standard drugs vs chloroquine-proguanil, Outcome 1 Clinical cases of malaria.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Any standard drugs vs chloroquine-proguanil, Outcome 2 Any adverse outcome.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Any standard drugs vs chloroquine-proguanil, Outcome 3 Dermatological adverse outcome.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Any standard drugs vs chloroquine-proguanil, Outcome 4 Gastrointestinal adverse outcome.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Any standard drugs vs chloroquine-proguanil, Outcome 5 Neuropsychiatric adverse outcome.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Any standard drugs vs chloroquine-proguanil, Outcome 6 Serious adverse event.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Any standard drugs vs chloroquine-proguanil, Outcome 7 Discontinuation of study drug for any reason.
View Full Article (HTML) Summary (61K)Standard (631K)Full (843K)